Press Room

Guy Villax speaker at 2017 PDA/FDA Conference

Start
Monday, September 11, 2017 - 10:45
End
Monday, September 11, 2017 - 11:45
Location: Washington DC, United States

Presentation Title: Investing in Quality to Meet Business Objectives

10:45 a.m. – 11:15 a.m.

guy villax portrait photo Hovione

Guy Villax

Non-Executive Board Member

Degree in Accounting and Financial Management

Guy Villax has a degree in Management from the University College at Buckingham, UK.

Guy Villax was Hovione's Chief Executive from 1997 to 2022, having previously worked at Price Waterhouse in London and Hovione in Asia.

Guy holds leadership positions at industry associations and in Portuguese state organizations: Rx-360, Health Cluster Portugal, Portugal’s Business Roundtable; and the ANI (Portugal’s National Innovation Agency) and the CNCTI (National Council for Science, Technology and Innovation).

 

 

 

 

Session: Current Quality Challenges for Pharmaceutical Executives

As the biopharmaceutical industry continues to evolve, major challenges associated with globalization and complexity of the supply chain emerge. In addition, companies now face internal pressures related to the cost of medicines, dealing with various global regulatory frameworks and changing expectations in evolving healthcare systems. The challenges have led an industry drive to adopt new business and quality technologies and to pursue partnerships with global regulators to help companies understand and facilitate implementation of changing regulations. This session will focus on major challenges that quality professionals should be aware as they interact with executives at their firms, how ensuring quality can play a part in overcoming those challenges and the crucial role of the executive in driving quality within the company.

 

The 2017 PDA/FDA Joint Regulatory Conference is the premier pharmaceutical manufacturing event where you can engage directly with U.S. FDA representatives and industry experts! Over two and a half information-packed days, FDA regulators will provide updates on current efforts affecting the development of global regulatory strategies, and industry experts will present case studies illustrating how they use global strategies to improve the quality of medical products. Hear what the Conference Co-chairs and past attendees have to say about this exciting event!

 

Live from PDA/FDA: Culture of Quality 

Empowering employees with a strong sense of ownership can lead to improved outcomes and increased cost efficiency.

 

 

You might be also interested in:

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026